HLS Therapeutics Inc. (HLTRF)

Market Cap	112.68M
Revenue (ttm)	56.77M
Net Income (ttm)	-17.99M
Shares Out	n/a
EPS (ttm)	-0.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,500
Average Volume	2,039
Open	3.660
Previous Close	n/a
Day's Range	3.660 - 3.710
52-Week Range	2.220 - 3.710
Beta	1.10
RSI	64.91
Earnings Date	Aug 7, 2025

About HLS Therapeutics

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders, central nervous system, and cardiovascular disease in Canada, the United States, and internationally. The company’s lead products include Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care de...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Craig Millian
• Employees: 92
• Stock Exchange: OTCMKTS
• Ticker Symbol: HLTRF

Financial Performance

In 2024, HLS Therapeutics's revenue was $56.62 million, a decrease of -10.23% compared to the previous year's $63.07 million. Losses were -$19.66 million, -28.61% less than in 2023.